TrialNature communications2022

Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration.

Ying Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.